ALXO (Alx Oncology Holdings Inc) — AI Stock Analysis & Recommendation

Research of August 13, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate ALXO a HOLD. The latest price is $0.98.

The research plan

• Entry: $1.94
• Time horizon: days

The current market regime and stock-specific factors do not support a new entry.

Why

The current market regime and stock-specific factors do not support a new entry. Catalysts to watch: Positive clinical trial data for evorpacept; Strategic partnerships in the oncology space; Potential for future regulatory approvals. Key risks: Pre-revenue status with substantial net losses and high debt; High clinical trial uncertainty and dependence on evorpacept's success; Significant historical drawdowns and high realized volatility.

What could push ALXO higher

• Positive clinical trial data for evorpacept.
• Strategic partnerships in the oncology space.
• Potential for future regulatory approvals.

Key risks for ALXO

• Pre-revenue status with substantial net losses and high debt.
• High clinical trial uncertainty and dependence on evorpacept's success.
• Significant historical drawdowns and high realized volatility.

What each AI research team found

Fundamental team: Bearish · valuation: speculative

ALXO is a pre-revenue biotech with a highly speculative valuation driven by future drug development potential. While the company has a promising lead candidate and sufficient cash runway, the lack of current revenue, persistent net losses, and high debt-to-equity ratio present significant risks. The strong analyst consensus is noted but is not sufficient to overcome the fundamental challenges at this stage.

• ALXO is a pre-revenue biotech with $0 revenue and substantial ongoing net losses (-$101.7 million in 2025).
• The company has a very high debt-to-equity ratio of 8.105, indicating significant financial risk.
• Profitability metrics are zero across the board (gross, operating, and net margins), highlighting a lack of current operational profitability.

Technical team: Neutral

The technical analysis indicates a neutral stance for ALXO, with price consolidating near resistance and mixed signals across trend, volume, and momentum indicators. While there's no strong directional conviction, the proximity to resistance and potential distribution volume suggest a higher risk of a short-term pullback.

• Price is consolidating near resistance with mixed signals, suggesting a neutral outlook with potential for a short-term pullback.
• The stock is trading in a sideways range with volume generally below average, suggesting a lack of clear direction, but a recent volume spike on a down day hints at potential selling pressure.
• The price is consolidating near a resistance level with neutral momentum across all indicators, suggesting a sideways trend with potential for a breakout or breakdown.

Sentiment team: Neutral

ALX Oncology's sentiment remains neutral across news, social, and analyst perspectives, reflecting a balance between promising clinical developments and ongoing concerns. While positive trial data and institutional support offer upside potential, dilution risks and regulatory hurdles create a cautious outlook, leading to a stable sentiment momentum.

• ALX Oncology's news flow is neutral, characterized by promising clinical trial data for its lead drug candidate and positive earnings, offset by increasing short interest. (Score: 0)
• ALX Oncology Holdings (ALXO) exhibits a neutral sentiment driven by promising clinical programs and strategic partnerships, but tempered by significant dilution concerns and cautious analyst/technical signals. (Score: 0)
• ALX Oncology (ALXO) exhibits a neutral sentiment driven by a strong institutional and analyst buy-side consensus, offset by regulatory hurdles and past financial performance concerns.

Risk team: High

ALXO presents a HIGH risk profile due to significant clinical trial uncertainty, a history of extreme drawdowns, and high volatility. The company's unproven business model and negative cash flow further exacerbate these risks. Given the substantial downside potential and speculative nature, a SMALL position size with a tight stop-loss is recommended.

• Clinical Trial Uncertainty: ALXO's valuation is heavily dependent on the success of evorpacept, a drug targeting the CD47 pathway, which has seen past failures. The FDA's request for a Phase 3 study and discontinuation of evorpacept evaluations for certain...
• Deep 1-Year Drawdown: ALXO has experienced a maximum drawdown of -97.69% over the past year, indicating extreme historical downside risk and significant investor losses.
• High Realized Volatility: The stock exhibits high realized volatility (64.37% annualized over 20 days, 78.55% over 60 days), indicating significant price swings driven by news and trial outcomes.

ALXO at a glance

Market value	$168.7M
Revenue growth (year over year)	-100.0%
Debt / equity	0.07

Every AI call on ALXO since July 31, 2026, and what happened next (6 calls) →

Research of August 13, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.